Financial Performance - The company's operating revenue for the reporting period was 67,363,245.41 yuan, a decrease of 21.84% compared to the same period last year [2] - The net profit attributable to shareholders was 1,180,325.54 yuan, down 75.06% year-on-year [2] - The basic earnings per share decreased by 75.00% to 0.01 yuan, while diluted earnings per share dropped by 100.00% to 0.00 yuan [2] - The total assets at the end of the reporting period were 934,063,765.94 yuan, a decrease of 2.69% from the previous year [2] Cash Flow Analysis - The net cash flow from operating activities was 14,859,155.99 yuan, an increase of 171.73% compared to the previous period [7] - The net cash flow from investing activities was 18,597,586.88 yuan, a decrease of 34.57% year-on-year [7] - The net cash flow from financing activities was -40,384,964.10 yuan, a significant decrease of 954.70% compared to the previous period [7] Shareholder Information - The total number of ordinary shareholders and the top ten shareholders' holdings were detailed, with the largest shareholder holding 18,402,400 shares [9] - The company has a significant relationship between major shareholders, indicating potential influence on corporate governance [9] Changes in Financial Indicators - The company experienced a 49.04% decrease in cash and cash equivalents due to investments in structured deposits and wealth management products [6] - The accounts receivable increased, leading to a 245.94% rise in credit impairment losses [7] - The company reported a 90.80% decrease in other non-current assets, primarily due to a reduction in equipment prepayments [6]

Company Overview - Tailin Biological Technology Co., Ltd. is located in Hangzhou, Zhejiang Province, established on January 8, 2002, and listed on January 14, 2020. The company specializes in the research, manufacturing, and sales of microbial detection and control technology systems, organic analysis instruments, and other pharmaceutical equipment [1]. Business Segmentation - The main business revenue composition is as follows: microbial detection technology series products account for 41.12%, sterile production and contamination control equipment series products account for 40.78%, organic analysis technology series products account for 11.15%, and others account for 6.95% [1]. Stock Performance - On October 27, Tailin Biological's stock fell by 5.14%, trading at 30.44 yuan per share, with a transaction volume of 85.03 million yuan and a turnover rate of 3.58%. The total market capitalization is 3.689 billion yuan [1]. Fund Holdings - According to data from major fund holdings, one fund under Nuoan Fund has a significant position in Tailin Biological. The Nuoan Multi-Strategy Mixed A Fund (320016) increased its holdings by 286,000 shares in the second quarter, bringing the total to 511,200 shares, which represents 0.44% of the fund's net value, making it the fourth-largest holding [2]. Fund Performance - The Nuoan Multi-Strategy Mixed A Fund (320016) was established on August 9, 2011, with a latest scale of 1.399 billion yuan. Year-to-date returns are 68.76%, ranking 345 out of 8,226 in its category; one-year returns are 84.01%, ranking 158 out of 8,099; and since inception, the return is 225.7% [2]. Fund Management - The fund is managed by Kong Xianzheng and Wang Haichang. As of the latest update, Kong has been in position for 4 years and 336 days, with a total fund asset size of 4.607 billion yuan, achieving a best return of 84.01% and a worst return of -16.74% during his tenure. Wang has been in position for 3 years and 98 days, managing assets of 2.529 billion yuan, with a best return of 71.06% and a worst return of -18.8% [3].

Group 1 - The core point of the news is that Tailin Bio (300813.SZ) reported its Q3 2025 results, revealing a total of 7 institutional investors holding shares, which amounts to 9.9005 million shares or 8.17% of the total share capital, with a decline of 1.10 percentage points compared to the previous quarter [1] - Institutional investors include Qingdao Gaode Investment Partnership, Zhejiang Tailin Biotechnology Co., Ltd. - 2025 Employee Stock Ownership Plan, and UBS AG among others, indicating a diverse range of institutional interest [1] - The report also mentions that 23 public funds were not disclosed in this period compared to the previous quarter, including notable funds such as NuAn Duo Strategy Mixed A and China Europe CSI 300 Index Quantitative Enhancement A [1] Group 2 - From the foreign investment perspective, there was one new foreign institution disclosed this quarter, which is CITIC Securities Asset Management (Hong Kong) Co., Ltd. - Client Funds [2] - The report indicates that several foreign institutions, including BARCLAYS BANK PLC and Goldman Sachs, were not disclosed in this period compared to the previous quarter, suggesting a potential shift in foreign investment interest [2]

Core Viewpoint - Tailin Bio (300813.SZ) reported a decline in revenue for the first three quarters of 2025, while net profit showed significant growth compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 213 million yuan, representing a year-on-year decrease of 12.08% [1] - Net profit attributable to shareholders of the listed company was 14.72 million yuan, reflecting a year-on-year increase of 30.13% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 13.05 million yuan, which is a year-on-year increase of 21.83% [1] - Basic earnings per share were 0.12 yuan [1]

Group 1 - The core viewpoint of the news is that Tailin Bio (SZ 300813) reported its third-quarter performance, showing a decline in revenue but an increase in net profit and earnings per share [1] Group 2 - For the first three quarters of 2025, the company's revenue was approximately 213 million yuan, a year-on-year decrease of 12.08% [1] - The net profit attributable to shareholders was about 14.72 million yuan, reflecting a year-on-year increase of 30.13% [1] - The basic earnings per share were 0.12 yuan, which is a year-on-year increase of 20% [1] Group 3 - As of the report, Tailin Bio's market capitalization was 3.9 billion yuan [2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江泰林生物技术股份有限公司 2025 年第三季度报告全文已于 2025 年 10 月 27 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露，敬请投资者注意查阅！ 证券代码：300813 证券简称：泰林生物 公告编号：2025-079 浙江泰林生物技术股份有限公司 关于 2025 年第三季度报告披露的提示性公告 特此公告。 浙江泰林生物技术股份有限公司董事会 2025 年 10 月 27 日 ...

1、审议通过《2025 年第三季度报告》 经审核，董事会认为董事会编制和审核公司 2025 年第三季度报告的程序符 合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了上 市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 浙江泰林生物技术股份有限公司(以下简称"公司")第四届董事会第十次会 议于 2025 年 10 月 17 日以电话、书面送达等形式发出通知，并于 2025 年 10 月 23 日在公司会议室以现场举手表决的方式召开。会议应出席董事 7 名，实际出 席董事 7 名。本次会议由叶大林先生召集和主持，公司董事会秘书及高级管理人 员列席会议。 本次会议的召开符合《中华人民共和国公司法》《公司章程》及有关法律、 行政法规的要求，会议合法、有效。 二、董事会会议审议情况 经与会董事审议，会议通过如下议案: 证券代码：300813 证券简称：泰林生物 公告编号：2025-080 浙江泰林生物技术股份有限公司 第四届董事会第十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 具体内容详见公司 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥67,363,245.41, a decrease of 21.84% compared to the same period last year[5] - The net profit attributable to shareholders was ¥1,180,325.54, down 75.06% year-on-year, while the net profit after deducting non-recurring gains and losses was -¥155,169.53, a decrease of 103.36%[5] - The company's basic earnings per share for the period was ¥0.01, down 75.00% year-on-year, while diluted earnings per share were ¥0.00, a decrease of 100.00%[5] - Total operating revenue decreased to ¥213,188,852.61 from ¥242,467,278.88, representing a decline of approximately 12.06% year-over-year[17] - Total operating costs decreased to ¥201,314,970.50 from ¥236,221,850.45, a reduction of about 14.77% year-over-year[17] - Net profit increased to ¥14,523,036.61 from ¥10,599,894.14, marking a growth of approximately 37.25% year-over-year[18] - The total comprehensive income attributable to shareholders increased to ¥14,723,274.72 from ¥11,314,672.20, an increase of about 30.67% year-over-year[18] Cash Flow - The cash flow from operating activities showed a net inflow of ¥14,859,155.99, representing a significant increase of 171.73% compared to the previous year[5] - Operating cash inflow for the current period was 255,549,763.42 CNY, up from 233,795,795.59 CNY in the previous period, representing an increase of approximately 9.4%[19] - Net cash flow from operating activities improved to 14,859,155.99 CNY from a negative 20,714,994.54 CNY in the previous period[19] - Cash inflow from investment activities totaled 763,283,824.00 CNY, compared to 569,235,804.24 CNY in the previous period, marking an increase of approximately 34%[20] - Net cash flow from investment activities was 18,597,586.88 CNY, down from 28,422,441.32 CNY in the previous period[20] - Cash flow from financing activities resulted in a net outflow of 40,384,964.10 CNY, compared to a net inflow of 4,725,027.41 CNY in the previous period[20] - The company received 11,174,000.00 CNY from financing activities, down from 15,645,426.70 CNY in the previous period[20] - Total cash outflow for operating activities was 240,690,607.43 CNY, compared to 254,510,790.13 CNY in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥934,063,765.94, a decrease of 2.69% from the end of the previous year[5] - Total current assets decreased from 632,761,878.52 CNY to 545,192,536.68 CNY, a reduction of approximately 13.78%[15] - Cash and cash equivalents decreased from 264,872,528.62 CNY to 134,971,542.57 CNY, a decline of about 49.0%[15] - Accounts receivable increased from 43,546,552.81 CNY to 49,034,637.68 CNY, an increase of approximately 12.1%[15] - Inventory increased from 144,134,014.09 CNY to 153,639,950.20 CNY, an increase of about 6.0%[15] - Total liabilities increased to ¥143,919,186.72 from ¥139,178,386.25, an increase of approximately 5.30%[16] - The equity attributable to shareholders decreased to ¥790,144,579.22 from ¥820,050,345.31, a decrease of about 3.65%[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,437[11] - The largest shareholder, Ye Daling, holds 37.73% of shares, totaling 45,724,000 shares[11] - The second-largest shareholder, Ni Weiju, holds 15.18% of shares, totaling 18,402,400 shares[11] - The company has committed to a share transfer agreement with Ni Weiju, locking in 12.1 million shares for 12 months[12] Other Financial Metrics - The company reported a significant increase in intangible assets, which rose by 153.85% to ¥27,715,686.10, primarily due to land purchases[8] - The company experienced a 245.94% increase in credit impairment losses, amounting to -¥1,457,109.13, due to an increase in accounts receivable[9] - The company reported a financial expense of -¥5,896,688.66, compared to a financial expense of ¥3,361,208.48 in the previous period, reflecting a significant change in financial performance[18] - Research and development expenses remained stable at ¥49,120,227.85 compared to ¥49,454,422.64, indicating a slight decrease of 0.68%[18] - The deferred income tax liabilities decreased to ¥3,225,150.58 from ¥3,393,283.59, a reduction of approximately 4.95%[16] Audit Information - The company did not undergo an audit for the third quarter financial report[21]

Investment Rating - The report maintains a "Recommended" investment rating for the mechanical industry [6]. Core Insights - The mechanical industry is experiencing steady growth, particularly in the low-altitude economy and machinery sectors, supported by policy initiatives and technological advancements [3][4]. - The report highlights a significant increase in excavator sales, with a total of 19,858 units sold in September 2025, marking a year-on-year growth of 25.4%, including a domestic sales increase of 21.5% and an export increase of 29% [3]. Weekly Market Review - From October 13 to October 17, 2025, the Shanghai Composite Index decreased by 1.47%, while the ShenZhen Component Index and the ChiNext Index fell by 4.99% and 5.71%, respectively. The Shenwan Mechanical Equipment Index dropped by 5.84%, underperforming the CSI 300 Index by 3.62 percentage points, ranking 27th among 31 Shenwan first-level industries [11]. - Within sub-sectors, the performance varied, with general equipment down by 5.62%, specialized equipment down by 5.74%, rail transit equipment II down by 2.22%, engineering machinery down by 3.04%, and automation equipment down by 9.06% [11]. Key Sector Tracking - **Low-altitude Economy**: The Suzhou Development and Reform Commission released a dual list of capabilities and demands for the low-altitude economy, indicating strong local enterprise involvement in aircraft development and operations [3]. - **Machinery Equipment**: The report emphasizes the competitive advantage of domestic leading enterprises in both supply and demand, with a positive outlook for the engineering machinery sector [3]. Investment Recommendations - For the low-altitude economy, recommended companies include Deep City Transportation, Sujiao Science and Technology, Huasheng Group, and Nairui Radar. In the complete machine sector, focus on Wan Feng Ao Wei, Yihang Intelligent, Zongheng Co., and Green Energy Hui Charge. Key component manufacturers include Zongshen Power, Wolong Electric Drive, Yingliu Co., and Yingboer. In air traffic management and operations, consider CITIC Heli, Zhongke Xingtu, and Sichuan Jiuzhou [4]. - In the machinery equipment sector, recommended companies include Juxing Technology, Quan Feng Holdings, and Nine Company for the export chain, and Sany Heavy Industry, XCMG, and Anhui Heli for engineering machinery [4]. Economic Data Tracking - The report tracks various economic indicators, including the manufacturing PMI and fixed asset investment completion rates, which provide insights into the overall health of the manufacturing sector [40][44].

Core Viewpoint - Tailin Bio (300813) announced the acquisition of 2 patent certificates by its wholly-owned subsidiaries, Zhejiang Tailin Life Science Co., Ltd. and Zhejiang Tailin Analytical Instruments Co., Ltd. [1] Company Summary - Tailin Bio's subsidiaries have recently obtained 2 patent certificates, indicating a focus on innovation and potential growth in their product offerings [1]